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Abstract
The main clinical challenge in the management of thyroid cancer is to avoid
over-treatment and over-diagnosis in patients with lower-risk disease while
promptly identifying those patients with more advanced or high-risk disease
requiring aggressive treatment. In recent years, novel clinical and molecular
data have emerged, allowing the development of new staging systems,
predictive and prognostic tools, and treatment approaches. There has been a
notable shift toward more conservative management of low- and
intermediate-risk patients, characterized by less extensive surgery, more
selective use of radioisotopes (for both diagnostic and therapeutic purposes),
and less intensive follow-up. Furthermore, the histologic classification; tumor,
node, and metastasis (TNM) staging; and American Thyroid Association risk
stratification systems have been refined, and this has increased the number of
patients in the low- and intermediate-risk categories. There is now a need for
new, prospective data to clarify how these changing practices will impact
long-term outcomes of patients with thyroid cancer, and new follow-up
strategies and biomarkers are still under investigation. On the other hand,
patients with more advanced or high-risk disease have a broader portfolio of
options in terms of treatments and therapeutic agents, including multitarget
tyrosine kinase inhibitors, more selective BRAF or MEK inhibitors, combination
therapies, and immunotherapy.
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Introduction
The incidence of differentiated thyroid cancer (DTC) continues 
to rise worldwide, mostly because of the growing use of power-
ful diagnostic tools that permit the discovery of an increasing 
number of small papillary thyroid cancers (PTCs). Mortality from 
DTC, however, has changed minimally over the past five decades: 
the vast majority of patients with DTC have indolent tumors. The 
main clinical challenge is to avoid over-diagnosis in patients with 
low-risk disease or benign thyroid nodules while promptly identi-
fying those patients with more advanced or high-risk tumors that 
require aggressive treatment approaches. In recent years, we have 
witnessed the emergence of new clinical and molecular data that 
have allowed the development of new staging systems, new pre-
dictive and prognostic tools, and new approaches to treatment. 
Here, we will review the main advances regarding the staging and 
management of DTC.
Pathologic definition and staging systems
The fourth edition of the World Health Organization histologic 
classification of endocrine tumors, published in June 20171, con-
tains important revisions, which may have a broad impact on clini-
cal practice. First, the follicular-derived neoplasms now include a 
new entity within the group of tumors with borderline histological 
features: the non-invasive follicular thyroid tumor with papillary 
nuclear features (NIFTP)2,3, an encapsulated follicular-variant PTC 
with no evidence of capsular or vascular invasion. NIFTPs may 
account for up to 20% of the tumors previously classified as PTCs. 
The word “cancer” has been eliminated from the definition of 
NIFTP to underline its excellent prognosis: no adverse outcomes 
(such as cancer-related death, distant or regional metastases, and 
structural or biochemical recurrence) have been recorded for these 
tumors. The explicitly stated objective is to reduce the intensity of 
treatment and follow-up and the psychological consequences of the 
diagnosis of cancer. This entity was first proposed by an interna-
tional panel of pathologists and other professionals and has been 
endorsed by the American Thyroid Association (ATA). However, 
the seemingly excellent outcomes still need to be confirmed in 
long-term prospective studies. The current evidence is retrospec-
tive and of only moderate quality2. Other relevant changes include 
the identification of 15 PTC variants and the distinction of fol-
licular thyroid cancers (FTCs) into three subgroups (minimally 
invasive FTCs with capsular invasion only, encapsulated angioin-
vasive FTCs, and widely invasive FTCs), which reflect the prog-
nostic relevance of vascular invasion. Given its unique molecular 
profile4, the oncocytic variant is now considered a separate entity 
and is referred to as Hürthle cell carcinoma. Poorly differentiated 
thyroid cancer is also a separate entity, in accordance with the Turin 
criteria5,6.
The American Joint Cancer Committee/Union Internationale 
Contre le Cancer TNM staging system for thyroid cancer takes 
into account patient age, the size and extent of the primary thy-
roid tumor (T), lymph node involvement (N), and the presence of 
distant metastases (M). This system is aimed at predicting mor-
tality (not recurrences). The eighth edition of this staging system 
contains important modifications. The age cutoff was raised from 
45 to 55 years7, the presence of minimal extrathyroidal exten-
sion is no longer relevant for the T classification, and the tumor 
stages have been redistributed (Table 1 and Table 2). Regional 
lymph node metastases or the presence of gross extrathyroidal 
extension limited to strap muscle no longer mandate stage III 
but stage II. The presence of macroscopic invasion beyond strap 
muscle (subcutaneous tissue, larynx, trachea, esophagus in T4a 
tumors or carotid artery, prevertebral fascia or mediastinal vessels 
in T4b tumors) is an unfavorable prognostic factor. The overall 
goal of these modifications is to improve the accuracy of the 
system’s prediction of mortality8, restricting the assignment 
of higher risk to a small subset of patients (5–10%) with tumors 
classified as stage III (pT4a, any N, M0) or stage IV (pT4b, 
any N, M0, and M1). Implementation of the eighth edition 
revisions is expected to result in the down-staging of 
approximately 30–40% of patients with thyroid cancer9,10.
In the 2015 edition of its practice guidelines, the ATA also revised 
its system for stratifying the risk of recurrent disease. The new 
variables considered include new pathologic features of the tumor 
(for example, histopathological variant, vascular invasion, number 
of metastatic lymph nodes, size of the largest metastatic lymph 
node, and the presence of extranodal extension) as well as its 
molecular characteristics (mutational status of BRAF and the 
TERT promoter11, when available)12. These changes are expected 
to allow more precise estimates of the likelihood of recurrence.
The dynamic risk classification process used during follow-up 
assigns patients to one of four subgroups and may be modified at 
each follow-up examination: responses to therapy are classified as 
excellent, biochemically incomplete, structurally incomplete, or 
indeterminate response.
Management strategies
Current international guidelines advocate personalized decision-
making—based on the risk of recurrence and disease-specific 
death—regarding the extent of surgery, the use of radioactive 
iodine (RAI) therapy, the intensity and length of follow-up, and the 
degree of thyroid-stimulating hormone (TSH) suppression.
Active surveillance
The 2015 ATA guidelines include active surveillance 
among the management options for small subcentimeter PTCs. 
In pivotal Japanese studies, this strategy appeared to be both 
safe and effective13,14: after 10 years, very few patients had 
experienced tumor growth (8%), and the development of lymph 
node metastases was even less common (4%). Age below 40 
at diagnosis was an independent risk factor for disease 
progression15. In terms of cures, delayed surgical treatment of 
these tumors was as effective as immediate treatment15.
In a study conducted in the United States, 291 patients with cyto-
logically suspicious or malignant thyroid nodules (Bethesda 
class V or VI) measuring 1.5 cm or less were managed with 
active surveillance for a median of two years16. The percentages 
of tumors displaying growth were 2.5% at two years and 12% at 
five years. Independent predictors of growth were age under 
50 years and clinical judgment as “inappropriate for active 
surveillance”16. The latter label may be applied on the basis of 
nodule-related features (subcapsular location adjacent to the 
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Table 2. AJCC TNM seventh and eighth edition: stage.
Seventh edition Age <45 years Eighth edition Age <55 years
I Any T Any N M0 I Any T Any N M0
II Any T Any N M1 II Any T Any N M1
Seventh edition Age ≥45 years Eighth edition Age ≥55 years
I T1a/b N0 M0 I T1a/b 
T2
N0/NX 
N0/NX
M0 
M0
II T2 N0 M0 II T1a/b 
T2 
T3a/b
N1a/b 
N1a/b 
Any N
M0 
M0 
M0
III T1a/b 
T2 
T3
N1a 
N1a 
N0, N1a
M0 
M0 
M0
III T4a Any N M0
IVa T1a/b 
T2 
T3 
T4a
N1b 
N1b 
N1b 
N0, N1a, N1b
M0 
M0 
M0 
M0
IVa T4b Any N M0
IVb T4b Any N M0 IVb Any T Any N M1
IVc Any T Any T M1 - - - -
AJCC, American Joint Cancer Committee; TNM, tumor, node, and metastasis.
Table 1. AJCC TNM seventh and eighth edition: definitions.
Seventh edition Eighth edition
Tumor 
T1a: tumor ≤1 cm limited to the thyroid T1a: tumor ≤1 cm limited to the thyroid
T1b: tumor >1 cm but ≤2 cm limited to the thyroid T1b: tumor >1 cm but ≤2 cm limited to the thyroid
T2: tumor >2 cm but ≤4 cm limited to the thyroid T2: tumor >2 cm but ≤4 cm limited to the thyroid
T3: tumor >4 cm limited to the thyroid or minimal extrathyroid 
extension (for example, perithyroidal soft tissues or sternothyroid 
muscle) from a tumor of any size
T3a: tumor >4 cm limited to the thyroid 
 
T3b: gross extrathyroidal extension invading only strap muscles 
(sternohyoid, sternothyroid, thyrohyoid, omohyoid) from a tumor of 
any size
T4a: gross extrathyroidal extension invading subcutaneous soft 
tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve 
from a tumor of any size
T4a: gross extrathyroidal extension invading subcutaneous soft 
tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve 
from a tumor of any size
T4b: gross extrathyroidal extension invading prevertebral fascia or 
encasing the carotid artery or mediastinal vessels from a tumor of 
any size
T4b: gross extrathyroidal extension invading prevertebral fascia or 
encasing the carotid artery or mediastinal vessels from a tumor of 
any size
Node 
Nx: regional lymph nodes cannot be assessed Nx: regional lymph nodes cannot be assessed
N0: no evidence of locoregional lymph node metastasis N0a: one or more cytologically or histologically confirmed benign 
lymph nodes 
 
N0b: no radiologic or clinical evidence of locoregional lymph node 
metastasis
N1a: ipsilateral or bilateral metastasis to level VI (pretracheal, 
paratracheal, or prelaryngeal/Delphian) lymph nodes
N1a: ipsilateral or bilateral metastasis to level VI or VII (pretracheal, 
paratracheal, or prelaryngeal/Delphian, or upper mediastinal) lymph 
nodes; this can be unilateral or bilateral disease
N1b: metastasis to unilateral, bilateral, or contralateral lateral neck 
lymph nodes (levels I, II, III, IV, or V) or retropharyngeal or superior 
mediastinal lymph nodes (level VII)
N1b: metastasis to unilateral, bilateral, or contralateral lateral neck 
lymph nodes (levels I, II, III, IV, or V) or retropharyngeal lymph 
nodes
Metastasis 
M0: no distant metastasis M0: no distant metastasis
M1: distant metastasis M1: distant metastasis
AJCC, American Joint Cancer Committee; TNM, tumor, node, and metastasis.
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recurrent laryngeal nerve [RLN], suspicion of extrathyroidal 
extension, and invasion of the RLN or trachea—all three of which 
can be difficult to exclude on neck ultrasound [US]—fine-needle 
aspiration [FNA] cytology findings suggestive of an aggressive 
histotype, and a documented increase in size of at least 3 mm 
in a confirmed PTC) or patient-related factors (metastatic disease, 
age below 18 years, refusal of the surveillance-alone approach, 
poor adherence to the follow-up protocol) or physician-related 
factors (limited experience with thyroid cancer management 
or neck US or both) or a combination of these factors17.
Other observational clinical trials to evaluate the “active surveil-
lance” approach in subcentimeter PTCs are underway in Korea 
and Israel (NCT02952612, NCT02938702, and NCT02609685). 
Also, there is a need for biomarkers that can identify those rare 
microcarcinomas that are likely to grow, so they can be promptly 
referred for surgery.
Individualized surgical approaches
According to the ATA guidelines12, thyroid lobectomy (TL) may 
be used for low-risk, intrathyroidal tumors up to 4 cm in size with 
no lesions in the contralateral lobe. Total thyroidectomy (TT) was 
previously considered the preferred approach for these tumors. 
In a retrospective analysis of 52,173 cases in the Surveillance 
Epidemiology and End Results (SEER) database, TL for tumors 
measuring at least 1 cm was associated with small but statistically 
significant increases in the risks for recurrence (9.8% versus 7.7%) 
and mortality (2.9% versus 1.6%) compared with TT18. A recent ret-
rospective analysis with a more extensive risk stratification found 
no such difference in terms of overall survival19, but, in another 
meta-analysis, the risk of recurrence after TL was significantly 
higher than that after TT (8.3% versus 4.4%; p<0.01)20. It is 
worth noting that tumor recurrence in the contralateral lobe has 
been observed in 5% of patients treated with TL21 and that benign 
nodule relapse is reported in 20–50%22,23. Levothyroxine treat-
ment has been reported to prevent benign nodule relapse, but the 
evidence for this effect is limited24.
TL offers several advantages over TT. First, the rate of side 
effects is lower with TL. It virtually eliminates the risks of per-
manent hypoparathyroidism and bilateral RLN palsy25 and 
reduces the rates of permanent unilateral RLN palsy (0.6% 
in TL versus 1.3% in TT)25. Second, surgical hypothyroidism 
after TT requires lifelong levothyroxine (LT4) replacement 
therapy. The rate of hypothyroidism after TL varies from 
23.6 to 47%26,27, and patients with a normal serum TSH level 
may not require LT4 treatment at all. TL and TT are also 
believed to have differential effects on the patient’s qual-
ity of life. However, two relatively small studies have failed 
to detect any difference28,29 and thus further investigation 
of this issue is needed.
The ATA guidelines do not advocate prophylactic central neck dis-
section for low-risk patients12 despite the high frequency of subclin-
ical lymph node metastasis in DTC30. In fact, microscopic lymph 
node metastases that are not clinically detected before surgery 
have a questionable role in patient outcome31, and central 
compartment neck dissection carries an increased rate of 
surgical complications, hypoparathyroidism in particular32,33. In a 
prospective study of patients with no preoperative evidence of 
lymph node metastasis who were randomly assigned to undergo 
TT alone or TT with central compartment neck dissection, no 
difference in outcomes was found after five years of follow-up32.
Radioiodine remnant ablation: selective use
In the past, routine use of RAI ablation therapy after surgery was 
justified first by the need to eliminate residual normal thyroid tis-
sue, to achieve an undetectable serum thyroglobulin (Tg) level. It 
also allowed the identification of persistent neoplastic tissue with 
a 131I whole-body scan (WBS) and was likely to destroy any occult 
nests of neoplastic cells, thereby improving long-term outcomes. 
These indications have been questioned in recent years12,34,35. 
The ATA guidelines now recommend selective use of RAI based 
on individual risk12. Claiming uncertainties and ambiguities in the 
evidence, the European Association of Nuclear Medicine refused 
to endorse these recommendations36 and noted that there are no 
prospective, controlled study data that allow us to identify the 
patients with low-risk DTC who may not benefit from RAI abla-
tion. However, the Association did not emphasize that a treatment 
should be given only in patients in whom it may be beneficial and 
did not acknowledge that uncertainties persist concerning benefits 
of RAI administration in low- and intermediate-risk patients.
It is generally agreed that RAI has no role in the management of 
patients with intra-thyroidal microcarcinomas. In other low- and 
intermediate-risk patients, the decision to ablate can be based on 
individual prognostic factors and on the serum Tg level measured 
6 weeks after surgery either on LT4 treatment with a sensitive 
assay or following recombinant human TSH (rhTSH) injections. 
An undetectable or a low serum Tg level at that time supports a 
decision to avoid RAI administration. When it is indicated, it 
should consist of the administration of 1.1 GBq following rhTSH 
injections37.
Two randomized clinical trials in Europe are enrolling low-risk 
patients and aim to obtain reliable data on the indications for 
post-operative RAI administration. In the ESTIMABL2 trial 
(NCT01837745) being conducted in France, 750 patients with a 
T1bN0,Nx tumor will be randomly assigned to post-operative 
ablation with an activity of 30 mCi after rhTSH stimulation or 
simple follow-up. The IoN trial in the UK (NCT01398085) has a 
similar design. The primary outcomes in the two studies are 
disease-free survival rates at 3 and 5 years, respectively.
Follow-up tools
The main tools used for the follow-up of DTC are neck US and 
serum Tg determination38. Undetectable serum Tg levels can reli-
ably identify disease-free patients and have a negative predic-
tive value close to 100%. In contrast, early minimally detectable 
levels have a low positive predictive value: the majority of 
patients with these findings remain free of structural disease dur-
ing prolonged follow-up39. Tg trends over time—instead of abso-
lute alues—should be monitored: declining levels are reassuring, 
whereas increases suggest the presence of growing thyroid tissue 
(normal or neoplastic)40. In the presence of Tg autoantibodies 
(TgAbs), serum Tg levels determined by immunometric assays 
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may be falsely low. In these cases, management can be guided 
by the temporal trends in the TgAb titers themselves41. Novel 
biomarkers are emerging as replacements for serum Tg in these 
difficult cases, such as circulating microRNAs and other nucleic 
acids, but still need to be standardized and clinically validated42–44. 
The use of mass spectrometry for measuring serum Tg levels in 
the presence of TgAb also needs to be validated45,46. Sensitive Tg 
assays that can detect serum concentrations as low as 0.1 ng/mL 
are currently used and provide similar information on disease 
status as rhTSH-stimulated Tg obtained in the past with assays 
that had a sensitivity of 1 ng/mL. RhTSH-stimulated Tg levels 
are now measured during the follow-up only in those few patients 
with low but detectable serum Tg on LT4 treatment47. In 
these patients, a substantial increase in the stimulated Tg level 
may indicate the presence of neoplastic tissue.
Neck US provides useful information. PTC almost always spreads 
first to the cervical lymph nodes, where it can be identified sono-
graphically using specific criteria48, thus eliminating the need for 
diagnostic 131I WBS. US is more cost-effective, eliminates radia-
tion exposure, and has no adverse effects. Surgical treatment of 
lymph node metastases is recommended for lesions with smaller 
diameters exceeding 10 mm (for lateral N1) or 8 mm (for central 
N1), and there is no need for discovering small N1 of only a few 
millimeters in diameter. However, US is notoriously operator-
dependent, and some findings are non-specific and classified as 
indeterminate. Lesions with such features display significantly 
lower rates of persistence and growth than those with more sus-
picious US characteristics49. Suspicious findings can be confirmed 
by US-guided FNA with cytologic assessment and assay of Tg in 
the needle-washout fluid50. Distant metastases are rare in patients 
with negative findings on neck US. However, in the presence of 
rising Tg levels or suspicious clinical features, second-line func-
tional (diagnostic 131I WBS and 18-fluorodeoxyglucose positron 
emission tomography scan) or cross-sectional (computed tomog-
raphy or magnetic resonance imaging) imaging studies may be 
performed51.
Risk assessment is a dynamic process: the response to therapy is 
re-assessed on the basis of findings at each follow-up visit and 
expressed as excellent, indeterminate, biochemically incomplete, 
or structurally incomplete12,39,52. During long-term follow-up, 
even patients who initially displayed a high risk of persistent or 
recurrent disease can be re-classified as having lower-risk disease, 
and their follow-up program can be less intensive than originally 
planned. Lifelong surveillance is still recommended12. However, 
over 75% of recurrent lesions are identified within the first five 
years of follow-up, and late recurrence is very unlikely in low- or 
intermediate-risk patients with excellent responses to treatment53.
TSH stimulates the proliferation of normal and neoplastic 
thyrocytes54, and levothyroxine treatment significantly reduces 
DTC recurrence and cancer-related mortality55. The optimal 
TSH level is unclear. TSH suppression increases the risk for 
atrial fibrillation and osteoporosis in older patients and the risk of 
angina in patients with ischemic heart disease56. Suppres-
sive therapy should take into account both the likelihood of 
complications and the risk of increasing tumor cell proliferation. 
For this reason, levothyroxine treatment is no longer recommended 
for low- and intermediate-risk patients with no evidence of 
disease. The goal in these cases is a serum TSH level within the 
normal range. Suppressive therapy is advocated only in patients 
with structural disease and no contraindications12.
Treatment of distant metastases
RAI (131I) is currently the first-line treatment for distant metas-
tases that are RAI-avid. Traditionally, thyroid hormone with-
drawal has been the preferred method of preparation for this type 
of patient because it is associated with higher neoplastic tissue 
uptake and slower clearance of RAI than that achieved with rhTSH 
preparation. Observational data have suggested that rhTSH prepa-
ration may also be effective in terms of response to treatment in 
these patients57, but the evidence in support of this conclusion is 
currently insufficient to recommend rhTSH use in patients with 
metastatic DTC12. The activity of RAI for the treatment of dis-
tant metastases can be calculated dosimetrically or a fixed empiric 
dose can be used. A large retrospective study of DTC patients with 
distant metastases found similar overall survival with the two 
approaches58 after adjustments for age and tumor burden59.
Radioactive iodine-refractory disease
RAI-refractory DTC is defined as persistent neoplastic tissue 
that does not take up RAI; disease characterized by heterogene-
ous RAI uptake (that is, some lesions are RAI-avid and others are 
not); or disease that progresses after RAI treatment despite RAI 
uptake12. Specific molecular profiles are more likely to result in 
RAI-refractory disease60,61. Even in the presence of distant metas-
tases, most patients have asymptomatic, slowly progressive dis-
ease. RAI-refractory patients should benefit from local treatments 
(surgery, external beam radiotherapy, or thermal ablation, depend-
ing on the site of the lesion and local expertise) if they have symp-
toms or a high risk of local complications.
When disease progression occurs at multiple sites in patients with 
target lesions of more than 1–2 cm in diameter, treatment with 
tyrosine kinase inhibitors (TKIs) should be considered.
Two multitarget TKIs have been approved for the treatment 
of RAI-refractory DTC in the United States and Europe: soraf-
enib and lenvatinib62,63. These drugs have been shown to prolong 
the progression-free survival of patients with progressive 
RAI-refractory DTC, as compared with placebo (10.8 versus 
5.8 months, hazard ratio [HR] 0.59 for sorafenib; 18.3 versus 
3.6 months, HR 0.21 for lenvatinib), and objective response rates 
were 12% and 65%, respectively62,63. However, multitarget TKIs 
have side effects64. Greater experience in their use and better 
knowledge of the risk factors for these adverse effects65,66 are 
likely to improve their tolerance.
For BRAF- or ALK-mutant tumors, specific inhibitors may be 
used64,67. Treatments capable of restoring RAI uptake have attracted 
great interest. Selumetinib (a selective MEK inhibitor) and dabraf-
enib (a selective BRAF inhibitor used in BRAF-mutated tumors) 
have been shown to increase RAI uptake by RAI-refractory 
tumor tissues68,69, and these encouraging results are now under 
investigation (NCT02393690 and NCT03244956). Immuno-
therapy also appears to be a promising approach to thyroid can-
cer, alone or in association with other drugs70 (NCT02390739 
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and NCT03181100). These agents have yet to be approved by 
regulatory agencies, such as the U.S. Food and Drug Administra-
tion and the European Medicines Agency. Enrollment in clinical 
trials for patients with progressive metastatic disease should be 
considered and encouraged in order to improve both clinical case 
outcomes and medical knowledge in the field71.
Conclusions
In recent years, DTC treatment has become considerably more 
conservative, with less extensive surgery (or no surgery at all), 
reduced use of radioisotopes, and less intensive follow-up 
of low- and intermediate-risk patients. Furthermore, the systems 
used to histologically classify and stage DTCs have recently 
been refined, along with the ATA scheme for estimating their 
risk of recurrence, and more patients are now considered to be 
at low or intermediate risk. There is a need for new, prospec-
tive data to clarify how these changing practices will impact the 
long-term outcome of these patients. On the other hand, patients 
with more advanced or high-risk disease now have a broader 
portfolio of treatment options, including multitarget TKI ther-
apy, more selective BRAF inhibitors, combination therapies, and 
immunotherapy. However, the indications for each, their optimal 
starting times and dosing schedules, and their long-term safety 
profiles remain to be clarified in coming years.
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